A substantial body of research over the past decade has demonstrated that, even in the earliest stages, ovarian cancer pro-duces symptoms. This study by Ryerson and colleagues is a signifi cant contribution to that body of evidence and underscores the importance of including ovarian cancer in the differential diagnosis when a patient reports gynecologic, GI, or abdominal symptoms.
Early recognition is critical
Because we lack an effective screening test for ovarian cancer, early recognition and prompt evaluation of symptoms may be critical to improve prognosis. The cure rate for early-stage disease is 70% to 90%, compared with 10% to 30% for advanced stages.
This study is consistent with other research demonstrating that more than 80% of women with early-stage ovarian cancer have symptoms months before they are given a diagnosis. Compared with women who have GI symptoms, those who have gynecologic symptoms Experts agree: Ovarian cancer is not silent T he so-called silent killer isn't, apparently. That's the word from the Gynecologic Cancer Foundation, American Cancer Society, and Society of Gynecologic Oncologists, which jointly issued an evidence-based consensus statement on ovarian cancer symptoms in June. Often referred to as the "silent killer" because of the common belief that there are no warning signs or symptoms, ovarian cancer is the deadliest reproductive cancer.
Barbara A. Goff, MD, who comments here on the study by Ryerson and colleagues, helped formulate the consensus statement, which cites the following symptoms that occur in women with ovarian cancer:
• Bloating • Pelvic or abdominal pain • Diffi culty eating or feeling full quickly • Urinary symptoms (urgency or frequency).
A woman who has symptoms almost daily for more than a few weeks should see her gynecologist, and the gynecologist should include ovarian cancer in the differential diagnosis. Ovarian cancer should be suspected if symptoms persist more than 2 to 3 weeks and occur 12 or more times a month.
"This agreement on common symptoms of ovarian cancer hopefully will lead to earlier diagnosis when a cure is more likely," said Dr. Goff. "We know that when women are diagnosed in stage I of the disease, it is 90% curable."
For more on the detection of ovarian cancer, see Dr. Barbieri's editorial on page 8. underwent abdominal or pelvic imaging and surgical evaluation sooner after reporting symptoms.
C o p y r i g h t ® D o w d e n H e a l t h M e d i a

Large database and inclusion of ICD-9 data are strengths of this study
This study utilized population data from 13 geographic regions of the country. More important, it evaluated the ICD-9 diagnosis that prompted a visit to a physician or a procedure before ovarian cancer was diagnosed. Because women were unaware that they would subsequently be given a diagnosis of ovarian cancer, the design eliminates recall bias that has been at issue in earlier studies.
ICD-9 data are also a weakness
The fact that ICD-9 diagnostic data for billing purposes were used as a substitute for patient symptoms is a weakness of this study. Physicians frequently report only one ICD-9 diagnosis per encounter, so this study may signifi cantly underreport the symptoms experienced by women with ovarian cancer.
The fact that this study included only women older than 65 years is another weakness, as is the fact that only 3,250 of 8,357 women were ultimately included in the fi nal analysis-raising concern of selection bias.
Bottom line: Keep symptoms in mind
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